Internal Medicine, Gastroenterology · New Haven, CT
NPI
1336280080
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
40 Temple St, Suite 4a
New Haven, CT, 06510
Phone (203) 777-0304
Groups this clinician bills Medicare through
Medicare paid, 2024
$259K
11,142 services
Medicare patients, 2024
330
Average age 75
Drug cost, 2024
$3.4M
1,870 prescriptions
Company payments, 2023
$19.78
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Myron H Brand was code J3380 (injection, vedolizumab, intravenous, 1 mg), 7,200 times for 12 patients. In total Myron H Brand billed 11,142 services in 32 codes, and Medicare paid $259K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-02-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 7,200 | 12 | $17.37 | $125K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 1,620 | 12 | $24.91 | $40K |
| 99214 Office E&M - Established | Office | 439 | 204 | $98.12 | $43K |
| 99204 Office E&M - New | Office | 61 | 61 | $120.97 | $7,379 |
| 45380 Lower GI Endoscopy - Other | Facility | 59 | 58 | $105.30 | $6,213 |
| 43239 Upper GI Endoscopy | Facility | 54 | 54 | $66.15 | $3,572 |
| 45385 Colonoscopy - Lesion Removal | Facility | 30 | 30 | $217.76 | $6,533 |
| 96365 Intravenous Infusion, Hydration | Office | 26 | 14 | $53.21 | $1,383 |
| 96413 Chemotherapy Administration | Office | 25 | 13 | $110.16 | $2,754 |
| 96415 Chemotherapy Administration | Office | 24 | 12 | $23.33 | $560 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 18 | 18 | $188.64 | $3,396 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 16 | 15 | $13.46 | $215 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 14 | 14 | $175.49 | $2,457 |
By year: 2022 $562K for 27,852 services; 2023 $250K for 9,859 services; 2024 $259K for 11,142 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 30 | 30 | $17.84 | $535 |
| 82270 Immunoassay | 14 | 14 | $4.33 | $60.61 |
| 82272 Immunoassay | 13 | 13 | $4.18 | $54.39 |
Medicare prescription drug claims, 2024
In 2024, the drug Myron H Brand prescribed most often to Medicare patients was Omeprazole, with 322 prescriptions and refills. In total Myron H Brand wrote 1,870 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 322 | 884 | 103 | $4,647 |
| Mesalamine Generic | 202 | 420 | 43 | $128K |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 150 | 150 | 143 | $8,953 |
| Pantoprazole Sodium Generic | 140 | 405 | 46 | $1,776 |
| Dexlansoprazole Dr Dexlansoprazole | 71 | 199 | 20 | $29K |
| Esomeprazole Magnesium Generic | 60 | 156 | 19 | $2,079 |
| Famotidine Generic | 49 | 137 | 21 | $661 |
| Stelara Ustekinumab | 49 | 73 | Under 11 | $1.3M |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 42 | 50 | Under 11 | $2,086 |
| Lansoprazole Generic | 37 | 107 | 12 | $1,053 |
| Dicyclomine Hcl Generic | 33 | 45 | Under 11 | $425 |
| Prednisone Generic | 33 | 83 | 12 | $461 |
| Rinvoq Upadacitinib | 31 | 33 | Under 11 | $360K |
| Balsalazide Disodium Generic | 31 | 79 | Under 11 | $5,882 |
| Humira(Cf) Pen Adalimumab | 29 | 29 | Under 11 | $339K |
Brand drugs: 371 claims; generic drugs: 1,487 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Myron H Brand $19.78 ($19.78 in general payments such as food, travel and fees) from 1 company. The largest payer was Gilead Sciences, Inc. with $19.78.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 1 | $19.78 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.